8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Jan 8, 2026·SEC
KalVista Pharmaceuticals, Inc.(KALV)Earnings, Financials & Key Ratios
KALV•NASDAQ
$27.00
Price updated Jul 2, 2026
AboutKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Show more
- Revenue$74M
- EBITDA-$170M+8.9%
- Net Income-$164M+10.4%
- EPS (Diluted)-3.23+12.5%
- Gross Margin91.75%
- EBITDA Margin-231.45%
- Operating Margin-233.42%
- Net Margin-223.16%
- ROE-354.52%-191.8%
KALV Price & Volume
KalVista Pharmaceuticals, Inc. (KALV) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Mask Structural Solvency Risks
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Commercialization and dilution risk
Key Thesis Takeaways
- KalVista Pharmaceuticals faces a challenging transition from a milestone-dependent research entity to a commercial-stage biotechnology firm, characterized by significant operating losses and a deteriorating equity position.
- While the company maintains a cash balance of $229.3 million, the rapid accumulation of debt to $151.6 million by 2026Q4 and the erosion of equity into negative territory at -$2.7 million raise concerns regarding long-term capital sustainability.
- Investors should monitor the company's ability to generate recurring commercial revenue, as current financial performance remains heavily reliant on volatile, non-recurring milestone payments.
Verdict Logic
the company's reliance on non-recurring revenue and the shift to a debt-heavy capital structure, evidenced by a $151.6 million debt load against negative equity, suggests substantial execution and solvency risks.
KALV Growth Metrics
KalVista Pharmaceuticals, Inc. (KALV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years42.49%
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.87%
Return on Capital
10 Years-59.75%
5 Years-67.75%
3 Years-78.25%
Last Year-71.06%
KALV Recent Earnings
KalVista Pharmaceuticals, Inc. (KALV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 1/12 qtrs (17%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-64.9%
$39M
Q2 2026
May 7, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-65.0%
$39M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-65.0%
$39M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$1.01-87.0%
$0.54
Rev
$1M-73.4%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-64.9% |
| Q2 2026 | May 7, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-65.0% |
| Q2 2026 | May 5, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-65.0% |
| Q2 2026 | Mar 24, 2026 | $1.01vs $0.54-87.0% | $1Mvs $5M-73.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for KalVista Pharmaceuticals, Inc. (KALV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.00 | $1.44B | -8.36 | — | -223.16% | -354.52% | — | |
| $1.97 | $112.88M | 5.05 | — | — | -36.37% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $1.54 | $33.77M | -0.47 | — | — | -1335.64% | — | |
| $43.85 | $549.92M | 30.03 | 83.06% | 86.97% | 30.21% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — |
Compare KALV vs Peers
KalVista Pharmaceuticals, Inc. (KALV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KALV SEC Filings & Documents
KalVista Pharmaceuticals, Inc. (KALV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KALV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALV Frequently Asked Questions
KalVista Pharmaceuticals, Inc. (KALV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is KalVista Pharmaceuticals, Inc.'s revenue?
KalVista Pharmaceuticals, Inc. (KALV) reported $115.9M in revenue for fiscal year 2026. This represents a 7436% increase from $1.5M in 2013.
Is KALV profitable?
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $138.4M for fiscal year 2026.
Dividend & Returns
What is KALV's return on equity?
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -354.5%. Negative ROE indicates the company is unprofitable.
What is KalVista Pharmaceuticals, Inc.'s free cash flow?
KalVista Pharmaceuticals, Inc. (KALV) had negative free cash flow of $23.8M in fiscal year 2026, likely due to heavy capital investments.